Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Therapies
Positive Results from CVBT's Phase I No-Option Heart Disease Clinical Trial Will Be Presented at the American Heart Association's Annual Meeting
November 22nd, 2007
On the heels of FDA authorization to initiate Phase II clinical trials for severe coronary heart disease patients, CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) announced that findings from its initial clinical protocol for its protein drug candidate will be presented by Dr. Lynne Wagoner at the American Heart Association's Scientific Session to be held Nov. 4-7 in Orlando, Florida. Results from the Phase I trial using CVBT's human fibroblast growth factor 1 (FGF-1) indicated that the drug candidate was a safe and biologically-active treatment for patients with severe heart disease. The study was conducted at medical centers across the U.S. and confirmed results...
Source: Genetics & Environmental Business Week (2007-11-22)
|
